Trial Profile

Collaborative Study to Evaluate Heterologous Vaccination Against Covid-19 in Argentina

Status: Recruiting

Phase of Trial: Phase II

Latest Information Update: 08 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs AZD 1222 (Primary) ; Coronavirus vaccine-Wuhan Institute of Biological Products (Primary) ; COVID-19 vaccine-Gamaleya National Research Center of Epidemiology and Microbiology (Primary) ; Elasomeran (Primary)
Indications COVID 2019 infections
Focus Adverse reactions; Pharmacodynamics
Acronyms ECEHeVac

Most Recent Events

24 Sep 2021 Number of treatment arms have been increased from 13 to 14 by the addition of Active Comparator: Gam-COVID-Vac C1/ Gam-COVID-Vac C1 arm.
24 Sep 2021 Planned primary completion date changed from 12 Sep 2021 to 30 Sep 2021.
24 Sep 2021 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com